Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZN OTCMKTS:GSAC NASDAQ:MBIO NASDAQ:PWUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$3.28-4.1%$3.38$2.75▼$135.54$2.74M-0.31475,022 shs201,655 shsGSACGelStat$0.00$0.00$0.00▼$0.00$1.50M2.96544,073 shs127,659 shsMBIOMustang Bio$2.18-6.0%$1.48$0.89▼$24.00$10.16M2.161.62 million shs373,533 shsPWUPPowerUp Acquisition$0.36+2.7%$0.33$8.05▼$15.80$2.76M0.053,374 shs1.05 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro-4.09%+2.50%+8.61%-45.61%-90.82%GSACGelStat0.00%0.00%0.00%+33.33%+14.29%MBIOMustang Bio-6.03%-17.74%+103.74%+63.91%-88.12%PWUPPowerUp Acquisition+2.68%+2.80%+10.46%-37.32%-96.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALZNAlzamend Neuro2.2132 of 5 stars3.54.00.00.00.02.50.0GSACGelStatN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio0.7169 of 5 stars0.05.00.00.01.10.00.6PWUPPowerUp AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 3.00Buy$180.005,387.80% UpsideGSACGelStat 0.00N/AN/AN/AMBIOMustang Bio 0.00N/AN/AN/APWUPPowerUp Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A($31.66) per shareN/AGSACGelStatN/AN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/A($2.11) per shareN/APWUPPowerUp AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$9.95MN/A0.00N/AN/AN/A-497.73%-147.21%7/29/2025 (Estimated)GSACGelStatN/AN/A0.00∞N/AN/AN/AN/AN/AMBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)PWUPPowerUp AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest GSAC, ALZN, PWUP, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025N/AALZNAlzamend Neuro-$2.70N/AN/AN/AN/AN/A5/14/2025Q1 2025MBIOMustang BioN/A-$0.05N/A-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/AGSACGelStatN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/APWUPPowerUp AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A5.445.44GSACGelStatN/AN/AN/AMBIOMustang BioN/A1.341.34PWUPPowerUp AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%GSACGelStatN/AMBIOMustang Bio9.95%PWUPPowerUp Acquisition19.17%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro30.21%GSACGelStat20.50%MBIOMustang Bio0.21%PWUPPowerUp Acquisition48.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro4800,000559,000No DataGSACGelStat23.74 billion2.97 billionNot OptionableMBIOMustang Bio1004.38 million4.37 millionNot OptionablePWUPPowerUp AcquisitionN/A7.77 million4.04 millionNot OptionableGSAC, ALZN, PWUP, and MBIO HeadlinesRecent News About These CompaniesAspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 20, 2025 | finanznachrichten.deAspire Biopharma, PowerUp Acquisition complete business combinationFebruary 20, 2025 | markets.businessinsider.comAspire Biopharma announces public listing on NasdaqFebruary 20, 2025 | markets.businessinsider.comAspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 20, 2025 | accessnewswire.comAAspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 19, 2025 | accessnewswire.comA(PWUP) Technical Pivots with Risk ControlsFebruary 13, 2025 | news.stocktradersdaily.comNPowerUp Acquisition Corp trading resumesFebruary 12, 2025 | markets.businessinsider.comPowerUp Acquisition Corp trading halted, volatility trading pauseFebruary 12, 2025 | markets.businessinsider.comPowerUp Stock Soars to All-Time High of $14.84 Amidst Strong GrowthFebruary 11, 2025 | msn.comPowerUp Acquisition Corp. Approves Merger with Aspire BiopharmaFebruary 11, 2025 | msn.comWhen (PWUP) Moves Investors should ListenFebruary 2, 2025 | news.stocktradersdaily.comNPowerUp Acquisition Corp. Cl AJanuary 17, 2025 | wsj.comHow to Take Advantage of moves in (PWUP)January 12, 2025 | news.stocktradersdaily.comNPWUP PowerUp Acquisition Corp.December 12, 2024 | seekingalpha.comHow To Trade (PWUP)November 19, 2024 | news.stocktradersdaily.comNWhen the Price of (PWUP) Talks, People ListenOctober 18, 2024 | news.stocktradersdaily.comNSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP and ESGROctober 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, PWUP, RVNC, ESGR on Behalf of ShareholdersOctober 8, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP, ESGROctober 7, 2024 | accesswire.comA(PWUPU) Investment AnalysisSeptember 26, 2024 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGSAC, ALZN, PWUP, and MBIO Company DescriptionsAlzamend Neuro NASDAQ:ALZN$3.28 -0.14 (-4.09%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.34 +0.06 (+1.80%) As of 07/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.GelStat OTCMKTS:GSAC$0.0004 0.00 (0.00%) As of 07/17/2025 12:31 PM EasternGelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.Mustang Bio NASDAQ:MBIO$2.18 -0.14 (-6.03%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.19 +0.01 (+0.69%) As of 07/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.PowerUp Acquisition NASDAQ:PWUP$0.36 +0.01 (+2.68%) As of 07/17/2025PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
